Key Points
- Insider sale: Chief Accounting Officer Michael Dube sold 1,864 Intellia shares for approximately $23,170, reducing his holdings by 2.79%. The sale covered tax-withholding obligations from vested equity awards.
- Financial performance: Intellia reported a quarterly loss of $0.80 per share, in line with estimates, but revenue of $7.66 million missed expectations and fell 46.4% year over year. Analysts expect a full-year loss of $3.21 per share.
- Mixed outlook: NTLA has a consensus “Hold” rating and an average analyst price target of $20.72 versus a share price near $12.37. Institutional investors own 88.77% of the company, while analyst views range from “Strong Buy” to “Sell.”
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) CAO Michael Dube sold 1,864 shares of the firm's stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $12.43, for a total value of $23,169.52. Following the transaction, the chief accounting officer owned 65,022 shares in the company, valued at approximately $808,223.46. This trade represents a 2.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Intellia Therapeutics Stock Performance
NASDAQ:NTLA opened at $12.37 on Wednesday. The stock has a fifty day moving average price of $12.13 and a 200-day moving average price of $13.22. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -3.68 and a beta of 1.80. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting analysts' consensus estimates of ($0.80). The company had revenue of $7.66 million for the quarter, compared to analysts' expectations of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.Intellia Therapeutics's revenue was down 46.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.98) earnings per share. Research analysts predict that Intellia Therapeutics, Inc. will post -3.21 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on NTLA shares. Weiss Ratings restated a "sell (d-)" rating on shares of Intellia Therapeutics in a research report on Friday, July 17th. Citizens Jmp reiterated a "market outperform" rating and set a $30.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. Barclays started coverage on shares of Intellia Therapeutics in a research note on Tuesday. They issued an "underweight" rating and a $8.00 price objective on the stock. Citigroup restated a "market outperform" rating on shares of Intellia Therapeutics in a research note on Tuesday, August 25th. Finally, New Street Research set a $25.00 price target on Intellia Therapeutics in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have assigned a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $20.72.
View Our Latest Stock Analysis on NTLA
Institutional Investors Weigh In On Intellia Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its position in Intellia Therapeutics by 11.2% during the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company's stock worth $17,713,000 after acquiring an additional 139,325 shares during the last quarter. Royal Bank of Canada raised its position in Intellia Therapeutics by 1,082.1% in the first quarter. Royal Bank of Canada now owns 465,499 shares of the company's stock valued at $5,968,000 after purchasing an additional 426,121 shares during the last quarter. Headlands Technologies LLC bought a new position in Intellia Therapeutics in the second quarter valued at about $1,595,000. BlackRock Inc. acquired a new stake in shares of Intellia Therapeutics during the second quarter valued at about $260,721,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Intellia Therapeutics during the second quarter worth about $6,948,000. 88.77% of the stock is owned by institutional investors.
Intellia Therapeutics Company Profile
(
Get Free Report)
Intellia Therapeutics, Inc is a biotechnology company focused on developing genome-editing therapies using CRISPR/Cas9 technology. The company is working to create treatments that can directly modify disease-causing genes, including through in vivo approaches in which the editing machinery is delivered into a patient's body.
Its pipeline has included NTLA-2001, an investigational therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational program targeting kallikrein for hereditary angioedema.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
